Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts. Results From the Randomized DELAYED RRISC Trial

Journal of the American College of Cardiology

Volumn 50, Issue 3, 2007, Pages 261-267

  Vermeersch, Paul ^a   Agostoni, Pierfrancesco ^a   Verheye, Stefan ^a   Van den Heuvel, Paul ^a   Convens, Carl ^a   Van den Branden, Frank ^a   Van Langenhove, Glenn ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SAPHENOUS VEIN GRAFT; SURGICAL MORTALITY; THROMBOSIS; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CORONARY STENOSIS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; MALE; METALS; PROBABILITY; PROSTHESIS DESIGN; RETREATMENT; RISK ASSESSMENT; SAPHENOUS VEIN; SIROLIMUS; STATISTICS, NONPARAMETRIC; STENTS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447120247     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.05.010     Document Type: Article

References (27)

1. Moses J., Leon M., Popma J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Schofer J., Schluter M., Gershlick A.H., et al., E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
4. Schampaert E., Cohen E.A., Schluter M., et al., C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 (2004) 1110-1115
5. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al., BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). (published erratum appears in Lancet 2005;366:2086). Lancet 366 (2005) 921-929
6. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
7. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
8. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
9. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
10. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
11. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
12. Baim D. Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. J Am Coll Cardiol 42 (2003) 1370-1372
13. De Feyter P. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. Circulation 107 (2003) 2284-2286
14. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol 48 (2006) 2423-2431
15. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
16. In: Altman D.G., Machin D., Bryant T.N., and Gardner M.J. (Eds). Statistics with Confidence: Confidence Intervals and Statistical Guidelines. 2nd edition (2000), BMJ Books, London
17. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 356 (2007) 325-327
18. Mayor S. Drug eluting stents are safe for licensed indications, FDA panel says. BMJ 333 (2006) 1235
19. Chu W.W., Rha S.W., Kuchulakanti P.K., et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 97 (2006) 34-37
20. Wilson B.H., Humphrey A.D., Cedarholm J.C., et al. Drug-eluting stents are no better than bare metal in vein grafts: results from the strategic transcatheter evaluation of new therapies (STENT) group. (abstr). J Am Coll Cardiol 49 Suppl B (2007) 41B
21. Ellis S.G., Brener S.J., DeLuca S., et al. Late myocardial ischemic events after saphenous vein graft intervention-importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 79 (1997) 1460-1464
22. Keeley E.C., Velez C.A., O'Neill W.W., and Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
23. Bryan A.J., and Angelini G.D. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 9 (1994) 641-649
24. Depre C., Havaux X., and Wijns W. Pathology of restenosis in saphenous bypass grafts after long term implantation. Am J Clin Pathol 110 (1998) 378-384
25. Van Beusekom H., Van Der Giessen W., Van Suylen R., Bos E., Bosman F.T., and Serruys P.W. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 21 (1993) 45-54
26. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
27. Harrington R.A., and Califf R.M. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?. J Am Coll Cardiol 48 (2006) 2592-2595